<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Identifying patients at risk for fatal asthma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Identifying patients at risk for fatal asthma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Identifying patients at risk for fatal asthma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Mark Madison, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard S Irwin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Monica Kraft, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 10, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Assessing patient risk for a future fatal asthma exacerbation is important because many, if not most, asthma-related deaths are preventable if risk factors are recognized and addressed early [<a href="#rid1">1</a>].</p><p>The epidemiology and risk factors for fatal asthma are reviewed here. The evaluation and management of severe asthma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/564.html" rel="external">"Evaluation of severe asthma in adolescents and adults"</a> and  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults"</a>.)</p><p class="headingAnchor" id="H1720939967"><span class="h1">MORTALITY STATISTICS</span><span class="headingEndMark"> — </span>Asthma mortality varies among and within countries [<a href="#rid2">2-6</a>]. Based on World Health Organization (WHO) data, age standardized death rates per 100,000 range from 40.79 in Kiribati, 11.35 in India, 1.72 in China, 1.06 in Russia, 1.06 in the United Kingdom, 0.96 in France, 0.95 in the United States, 0.39 in the Netherlands, and 0.34 in Italy [<a href="#rid2">2</a>]. </p><p>In an analysis of the WHO database using a locally weighted scatter plot smoother (LOESS) curve for the 5 to 34-year age group weighted by the individual country population, asthma mortality was essentially unchanged from 2006 to 2012, after decreasing substantially from 1993 to 2006 [<a href="#rid4">4</a>]. The analysis included the 46 countries for which data were available. The decline in death rates from 1993 to 2006 is largely attributable to the widespread use of inhaled glucocorticoids for persistent asthma and avoidance of highly potent, poorly selective beta-agonists such as isoprenaline forte and fenoterol [<a href="#rid4">4</a>].</p><p>Similar to international trends, asthma mortality in the United States has declined since reaching a peak in the 1990s  (<a class="graphic graphic_figure graphicRef59239" href="/z/d/graphic/59239.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>]. From 2001 to 2015, United States deaths due to asthma decreased from 15 deaths per million population to 10.3 deaths per million population [<a href="#rid8">8,9</a>]. Among individuals with asthma, the rate of asthma deaths decreased from 2.1 per 10,000 persons in 2001 to 1.4 per 10,000 persons in 2009 [<a href="#rid8">8</a>].</p><p>In contrast, asthma deaths increased by 33 percent in the decade from 2008 to 2018 in England and Wales [<a href="#rid10">10</a>]. A review deemed that two-thirds of asthma deaths could have been prevented by basic asthma care to ensure regular review of asthma care, proper inhaler use, and a written asthma action plan.</p><p class="headingAnchor" id="H2"><span class="h1">DEMOGRAPHICS</span><span class="headingEndMark"> — </span>Patients who have frequent and severe asthma symptoms and evidence of airflow limitation are at greatest risk; however, cluster analysis has identified significant patient heterogeneity [<a href="#rid11">11</a>]. Fatal and near-fatal asthma exacerbations can occur sporadically and inexplicably in a minority of asthmatics whether the baseline level of disease activity is mild, moderate, or severe [<a href="#rid12">12,13</a>]. Therefore, any acute exacerbation of asthma may be a potentially fatal attack. (See  <a class="medical medical_review" href="/z/d/html/528.html" rel="external">"Acute exacerbations of asthma in adults: Home and office management"</a>.)</p><p>Group-based trajectory analysis has suggested three distinct clinical trajectories for patients with severe and/or difficult to control asthma [<a href="#rid14">14</a>]. In this study, 58 percent of patients with asthma had infrequent severe exacerbations during five-year follow-up, 32 percent improved, having fewer exacerbations in subsequent years, and 10 percent had persistently frequent exacerbations. Near-fatal asthma events occurred in all three trajectories but were significantly more frequent for patients in the trajectory with persistently frequent exacerbations.</p><p>In the United States, fatalities from asthma most commonly occur in lower income urban populations [<a href="#rid8">8,9,15</a>]. In 2019, the reported death rate from asthma per million population in the United States was 24 for non-Hispanic Black Americans, 10 for non-Hispanic White Americans, and 6 for Hispanic Americans, although data identifying Hispanic origin may not be strictly comparable [<a href="#rid9">9</a>]. Disparities in income, education, and access to health care are widely recognized as important contributors to differences in mortality rates among different sociodemographic groups. In this regard, an analysis showed that the higher risk of death in African American patients compared with White patients is not explained by race differences in deaths occurring in hospital and are therefore likely due to differences that precede hospitalization, such as differences in management at home or during transportation to the emergency department [<a href="#rid16">16</a>].</p><p>Even in the modern treatment era with an emphasis on inhaled glucocorticoids, mortality among asthmatic patients is mainly due to asthma. In a retrospective Australian study conducted from 2005 to 2009, 85 percent of 283 asthma-associated deaths were specifically due to asthma rather than to other comorbidities [<a href="#rid17">17</a>]. Notably, 70 percent of the deaths due to asthma had preventable or modifiable risk factors present.</p><p class="headingAnchor" id="H3"><span class="h1">TEMPORAL PATTERNS OF FATAL ASTHMA</span><span class="headingEndMark"> — </span>The pathology of acute severe asthma is complex and variable, possibly reflecting what may be different subtypes of the disease: slow onset and rapid onset  (<a class="graphic graphic_table graphicRef81440" href="/z/d/graphic/81440.html" rel="external">table 1</a>) [<a href="#rid18">18,19</a>]. Deaths from status asthmaticus are ultimately due to the consequences of severe airway obstruction, but the cause of the obstruction varies.</p><p class="headingAnchor" id="H4"><span class="h2">Slow onset fatal asthma</span><span class="headingEndMark"> — </span>Based on clinical and pathologic observations, it has been estimated that approximately 80 to 85 percent of patients who die of asthma have a history of progressive symptoms for more than 12 hours and often for one to three weeks. At autopsy, the airways of patients who die of this "slow-onset" asthma typically feature an eosinophilic inflammation and obstruction of airway lumens by tenacious mucus and desquamated epithelium [<a href="#rid20">20-22</a>]. These changes probably develop over days to weeks. This suggests that most of these patients would have had sufficient time to seek medical attention for worsening shortness of breath [<a href="#rid23">23,24</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Rapid onset fatal asthma</span><span class="headingEndMark"> — </span>In a minority of patients with fatal or near-fatal exacerbations of asthma, possibly up to 20 percent (8 to 14 percent of asthma exacerbations in general), death occurs less than 2 to 6 hours after symptom onset [<a href="#rid25">25-27</a>]. The airways of these patients with "rapid-onset" fatal asthma do not have eosinophil-predominant inflammation or widespread mucus plugging typical of status asthmaticus. Instead, severe airway obstruction appears to be mainly due to smooth muscle bronchospasm and neutrophils are the predominant inflammatory cell in the airway mucosa [<a href="#rid28">28,29</a>].</p><p>Unfortunately, specific characteristics that would help the clinician predict which patients are predisposed to rapid-onset asthma attacks have not been identified. Neither the severity of baseline asthma symptoms, years of asthma, smoking habits, asthma medication use, nor history of hospitalization for asthma help in identifying these patients. However, patients with rapid onset asthma exacerbations may more commonly report sensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) [<a href="#rid27">27</a>]. Rapid-onset asthma exacerbations do not appear to be due to anaphylaxis, although that diagnosis must be considered given the rapidity of the deterioration [<a href="#rid27">27,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/390.html" rel="external">"Fatal anaphylaxis"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">IDENTIFYING HIGH-RISK PATIENTS</span><span class="headingEndMark"> — </span>A number of potential risk factors for fatal or near-fatal asthma exacerbations have been identified.</p><p class="headingAnchor" id="H7"><span class="h2">Major risk factors</span><span class="headingEndMark"> — </span>Two elements of the clinical history are most useful in assessing risk for a future fatal or near-fatal asthma exacerbation in an individual patient  (<a class="graphic graphic_algorithm graphicRef76827" href="/z/d/graphic/76827.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Recent history of poorly controlled asthma – Recent history of poor or only partial control of asthma symptoms indicates increased risk. While no single symptom is predictive of an impending severe attack, increases in dyspnea and wheezing, frequency of nocturnal awakenings, use of short-acting, beta-adrenergic agonist rescue medications, and increased diurnal variability in peak expiratory flow rate (PEFR) all indicate a pattern of poor or partial control of asthma [<a href="#rid23">23,31,32</a>]. Hospitalization or emergency care visits in the past year, current or recent use of oral glucocorticoids, and lack of treatment with inhaled glucocorticoids are all indicative of poorly controlled asthma and should alert the physician to increased risk of asthma-related death [<a href="#rid33">33,34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior history of near-fatal asthma – Any past history of a prior near-fatal asthma exacerbation requiring endotracheal intubation and mechanical ventilation or a history of a prior intensive care unit admission for asthma should alert the clinician to the patient's propensity and high risk for near-fatal or fatal asthma exacerbations [<a href="#rid24">24,35-37</a>].</p><p></p><p>In a population-based case-control study, 71 percent of patients with a near-fatal asthma attack reported a prior history of intubation or cardiopulmonary resuscitation compared to only 6 and 2 percent in emergency department and community control subjects with asthma, respectively [<a href="#rid36">36</a>]. In a prospective case-control study, univariate analysis showed that the odds ratio for a second near-fatal attack was 28 among patients with a history of previous mechanical ventilation and 10 if there was a history of a prior admission to an intensive care unit [<a href="#rid24">24</a>]. A study of patients discharged after mechanical ventilation for near-fatal asthma showed a mortality rate of 10 percent at one year, 14 percent at three years, and 23 percent at six years [<a href="#rid37">37</a>].</p><p>Although a previous history of mechanical ventilation is high among patients being evaluated for near-fatal or fatal attacks, the lack of such prior history in an individual patient does not rule out the possibility of a potentially fatal attack and should not be reassuring to the clinician assessing risk [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Minor risk factors</span><span class="headingEndMark"> — </span>Other clinical features also have been linked to near-fatal or fatal asthma, but the associations are not as strong as the factors noted above  (<a class="graphic graphic_algorithm graphicRef76827" href="/z/d/graphic/76827.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sensitivity to aeroallergens</strong> – After adjusting for age and lung function (FEV<sub>1</sub>), patients with non-allergic asthma have a higher risk of mortality than patients with allergic asthma (relative risk 1.9) [<a href="#rid38">38</a>]. However, aeroallergen exposure, particularly due to pet ownership, is associated with episodes of near fatal and fatal asthma in sensitized individuals [<a href="#rid39">39,40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Food allergy</strong> – A history of food allergy in a patient with asthma may be a significant risk factor for asthma-related death. Importantly, deaths can occur in patients with a history of only mild prior reactions to a specific food [<a href="#rid34">34,41,42</a>]. (See  <a class="medical medical_review" href="/z/d/html/101088.html" rel="external">"Food intolerance and food allergy in adults: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a><strong> exacerbated respiratory disease (AERD)</strong> – For patients with AERD, exposure to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX)-1 can result in severe and potentially fatal asthma exacerbations  (<a class="graphic graphic_table graphicRef62880" href="/z/d/graphic/62880.html" rel="external">table 2</a>) [<a href="#rid43">43</a>]. Patients with AERD should avoid aspirin and NSAIDs  (<a class="graphic graphic_table graphicRef58651" href="/z/d/graphic/58651.html" rel="external">table 3</a>), unless they have been desensitized to aspirin. (See  <a class="medical medical_review" href="/z/d/html/520.html" rel="external">"Aspirin-exacerbated respiratory disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise</strong> – Exercise is an uncommon cause of fatal asthma but certain features have been observed in association with fatal events. In an eight year period in the United States, 61 episodes of fatal asthma were identified that were precipitated by exercise [<a href="#rid44">44</a>]. Most subjects were White males between the ages of 10 and 14. Basketball and track were the most common sports associated with fatal asthma. The level of asthma control of these individuals prior to participation in exercise was not reported. (See  <a class="medical medical_review" href="/z/d/html/533.html" rel="external">"Exercise-induced bronchoconstriction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Illicit drug use</strong> – Cocaine and heroin usage is a frequent trigger for severe acute asthma exacerbations: both are associated with a higher rate of intubation, and cocaine use is associated with a longer ICU length of stay [<a href="#rid45">45,46</a>]. In a retrospective study of hospital admissions for asthma in patients age 16 and older, 27.6 percent were cocaine users and 30.9 percent were heroin users [<a href="#rid45">45</a>]. Intubation and ICU admission were over 10 times more frequent among users compared with nonusers, even after controlling for cigarette smoking.</p><p></p><p class="bulletIndent1">Several mechanisms contribute to the adverse effect that cocaine and heroin have on asthma: direct thermal injury from smoking the drugs, IgE mediated allergy to cocaine, direct bronchoconstriction by cocaine, and an irritant effect on respiratory epithelium from cocaine or insufflated heroin [<a href="#rid45">45,46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Menstruation</strong> – An increased frequency of near-fatal asthma episodes at the time of menstruation has been reported [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory virus infection</strong> – In one series, evidence of respiratory viral infection, particularly picornavirus and adenovirus, was found in 59 percent of patients presenting to a hospital with near fatal asthma exacerbations [<a href="#rid48">48</a>]. However, it is notable that SARS-CoV-2 (COVID-19) pneumonia requiring hospitalization did not appear to induce severe exacerbations in patients with a history of asthma [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking and vaping</strong> – Current smoke exposure is predictive of acute care need for asthma, and both in-hospital and post-hospital mortality are increased in smokers who require mechanical ventilation for asthma [<a href="#rid37">37,40,50,51</a>]. Use of electronic nicotine delivery systems for vaping has not been definitively linked to fatal or near-fatal exacerbations of asthma per se, but asthmatics may represent a population especially vulnerable to the adverse effects of vaping [<a href="#rid52">52,53</a>]. Vaping has been associated with an increased number of days absent from school for asthma symptoms among high school students in South Korea, and second hand exposure to vaping aerosols was associated with increased self-reported asthma attacks in the 2016 Florida Youth Tobacco Survey [<a href="#rid54">54,55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other factors</strong> – Other features associated with fatal and near fatal asthma, particularly slow onset fatal asthma, include: long duration of asthma, systemic glucocorticoid dependence, non-adherence to therapy, poor asthma control, psychosocial problems and less adaptive personality, delay in obtaining medical care, older age, and comorbid conditions [<a href="#rid37">37,43,56-60</a>]. Noncompliance with inhaled glucocorticoids was high among patients who required mechanical ventilation for asthma (57 percent), but this was not different from other patients seen in the emergency department for acute asthma [<a href="#rid35">35</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Objective measures</span><span class="headingEndMark"> — </span>Several studies have observed that a low forced expiratory volume in one second (FEV<sub>1</sub>) is associated with an increased risk of asthma exacerbations and the lower the FEV<sub>1</sub>, the greater the risk [<a href="#rid40">40,61-64</a>]. In addition, air trapping and hyperinflation are associated with an increased frequency of serious asthma exacerbations [<a href="#rid65">65,66</a>]. As an example, in a prospective study of severe or difficult to control asthma, postbronchodilator forced vital capacity (FVC) less than 70 percent was a predictor of asthma related emergency department visits and hospitalization [<a href="#rid65">65</a>].</p><p>Despite these associations, patients with subsequent fatal or near fatal asthma may have entirely normal baseline spirometry.</p><p class="headingAnchor" id="H10"><span class="h2">Poor perception of dyspnea</span><span class="headingEndMark"> — </span>Other clinical or physiological features that have been noted in some asthmatics with a history of near-fatal asthma are reduced chemosensitivity to hypoxia, a poor perception of airway obstruction, a blunted perception of dyspnea, and difficulty communicating symptoms [<a href="#rid67">67-71</a>]. These phenomena could be important in explaining, at least in part, the apparent delays these patients sometimes have in seeking medical attention during an asthma exacerbation. While no specific aspects of the medical history can identify a patient with such a blunted sense of dyspnea, Borg scale scoring of dyspnea during resistive loading, exercise, and breath-holding maneuvers hold promise for better identification of these patients in the future [<a href="#rid72">72-74</a>]. (See  <a class="medical medical_review" href="/z/d/html/1477.html" rel="external">"Cardiac rehabilitation programs", section on 'Rating of perceived exertion (Borg scale)'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Only one-third of asthma mortalities in the United States in the year 2000 occurred in hospitalized patients, suggesting that many patients who ultimately die from asthma must either fail to seek medical attention during the hours or days of increased symptoms, or have a course of deterioration that is too rapid to reach hospital care in time, or are not appropriately hospitalized upon presentation [<a href="#rid16">16</a>]. Therefore, efforts to decrease mortality from asthma have focused on educating patients to recognize the symptoms of an attack early and to follow an appropriate action plan that includes prompt medical evaluation [<a href="#rid75">75,76</a>]. For patients who are at high risk of fatal asthma  (<a class="graphic graphic_algorithm graphicRef76827" href="/z/d/graphic/76827.html" rel="external">algorithm 1</a>), we prescribe <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (or equivalent) for the patient to keep on hand and start as advised by a prednisone-based action plan. (See  <a class="medical medical_review" href="/z/d/html/566.html" rel="external">"Asthma education and self-management"</a>.)</p><p>Efforts to modify risk factors for fatal and near fatal asthma include: avoidance of asthma triggers such as aeroallergens, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, and nonsteroidal anti-inflammatory drugs (NSAIDs); consideration of aspirin desensitization in aspirin sensitive patients; adherence to use of inhaled glucocorticoids; smoking and vaping cessation; appropriate treatment of exercise-induced bronchoconstriction; and avoidance of illicit drugs  (<a class="graphic graphic_table graphicRef58651" href="/z/d/graphic/58651.html" rel="external">table 3</a>). Patients with severe asthma should undergo evaluation for therapy with a biologic agent to reduce exacerbations. (See  <a class="medical medical_review" href="/z/d/html/551.html" rel="external">"Treatment of severe asthma in adolescents and adults", section on 'Persistently uncontrolled asthma'</a>.)</p><p>While patients do better than clinicians in assessing the severity of an asthma attack, subjective assessments of the severity of airway obstruction, by either patients or clinicians, are widely recognized as poor and insensitive. Use of objective measures such as peak expiratory flow rate, forced expiratory volume in one second (FEV<sub>1</sub>), and forced vital capacity (FVC) can be an important component of assessing asthma control and the severity of an acute exacerbation. (See  <a class="medical medical_review" href="/z/d/html/528.html" rel="external">"Acute exacerbations of asthma in adults: Home and office management"</a>.)</p><p class="headingAnchor" id="H3835398323"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112676.html" rel="external">"Society guideline links: Severe asthma in adolescents and adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112325.html" rel="external">"Society guideline links: Asthma in adolescents and adults"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Near-fatal and fatal asthma exacerbations may occur in patients with mild, moderate, or severe asthma and the course may be either slow or rapid in onset  (<a class="graphic graphic_table graphicRef81440" href="/z/d/graphic/81440.html" rel="external">table 1</a>). (See <a class="local">'Demographics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, fatalities from asthma most commonly occur in lower income, urban populations. (See <a class="local">'Demographics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recent history suggestive of poor asthma control or any prior history of endotracheal intubation and mechanical ventilation for asthma should alert the asthma care provider that the patient is at high-risk for fatal or near-fatal asthma exacerbations  (<a class="graphic graphic_algorithm graphicRef76827" href="/z/d/graphic/76827.html" rel="external">algorithm 1</a>). (See <a class="local">'Temporal patterns of fatal asthma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other clinical features, alone or in combination, may also suggest a high-risk patient: long duration of asthma, poor adherence to medical therapy, systemic glucocorticoid dependence, psychosocial problems, older age, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>/NSAID sensitivity, cigarette smoke exposure, prior hospitalization for asthma, and aeroallergen exposure in sensitized individuals. (See <a class="local">'Identifying high-risk patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Objective measures of airflow obstruction, such as spirometry or peak expiratory flow rate, obtained at the time of office visits may help predict which patients are at increased risk for future emergency department visits and hospitalization. (See <a class="local">'Objective measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poor perception of dyspnea has been noted in survivors of near-fatal asthma and likely contributes to delays in seeking medical care. (See <a class="local">'Poor perception of dyspnea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identifying patients prone to severe exacerbations is important because education of the patient and provision of a detailed action plan for these patients can reduce the risk of fatal or near-fatal asthma  (<a class="graphic graphic_table graphicRef58651" href="/z/d/graphic/58651.html" rel="external">table 3</a>). (See <a class="local">'Prevention'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Royal College of Physicians. Why asthma still kills: National Review of Asthma Deaths (NRAD). http://www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf (Accessed on May 16, 2014).</li><li class="breakAll">www.worldlifeexpectancy.com/cause-of-death/asthma/by-country (Accessed on September 22, 2017).</li><li><a class="nounderline abstract_t">Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW, et al. Trends and Patterns of Differences in Chronic Respiratory Disease Mortality Among US Counties, 1980-2014. JAMA 2017; 318:1136.</a></li><li><a class="nounderline abstract_t">Ebmeier S, Thayabaran D, Braithwaite I, et al. Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012). Lancet 2017; 390:935.</a></li><li><a class="nounderline abstract_t">Caffrey Osvald E, Bower H, Lundholm C, et al. Asthma and all-cause mortality in children and young adults: a population-based study. Thorax 2020; 75:1040.</a></li><li><a class="nounderline abstract_t">Lemmetyinen RE, Karjalainen JV, But A, et al. Higher mortality of adults with asthma: A 15-year follow-up of a population-based cohort. Allergy 2018; 73:1479.</a></li><li><a class="nounderline abstract_t">Moorman JE, Rudd RA, Johnson CA, et al. National surveillance for asthma--United States, 1980-2004. MMWR Surveill Summ 2007; 56:1.</a></li><li><a class="nounderline abstract_t">Moorman JE, Akinbami LJ, Bailey CM, et al. National surveillance of asthma: United States, 2001-2010. Vital Health Stat 3 2012; :1.</a></li><li class="breakAll">https://www.cdc.gov/asthma/most_recent_data.htm (Accessed on November 08, 2021).</li><li><a class="nounderline abstract_t">Iacobucci G. Asthma deaths rise 33% in past decade in England and Wales. BMJ 2019; 366:l5108.</a></li><li><a class="nounderline abstract_t">Sekiya K, Nakatani E, Fukutomi Y, et al. Severe or life-threatening asthma exacerbation: patient heterogeneity identified by cluster analysis. Clin Exp Allergy 2016; 46:1043.</a></li><li><a class="nounderline abstract_t">Romagnoli M, Caramori G, Braccioni F, et al. Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin Exp Allergy 2007; 37:552.</a></li><li><a class="nounderline abstract_t">Restrepo RD, Peters J. Near-fatal asthma: recognition and management. Curr Opin Pulm Med 2008; 14:13.</a></li><li><a class="nounderline abstract_t">Yii ACA, Tan JHY, Lapperre TS, et al. Long-term future risk of severe exacerbations: Distinct 5-year trajectories of problematic asthma. Allergy 2017.</a></li><li><a class="nounderline abstract_t">Eisner MD, Katz PP, Yelin EH, et al. Risk factors for hospitalization among adults with asthma: the influence of sociodemographic factors and asthma severity. Respir Res 2001; 2:53.</a></li><li><a class="nounderline abstract_t">Krishnan V, Diette GB, Rand CS, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med 2006; 174:633.</a></li><li><a class="nounderline abstract_t">Ali Z, Dirks CG, Ulrik CS. Long-term mortality among adults with asthma: a 25-year follow-up of 1,075 outpatients with asthma. Chest 2013; 143:1649.</a></li><li><a class="nounderline abstract_t">Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med 2005; 172:149.</a></li><li><a class="nounderline abstract_t">Ramnath VR, Clark S, Camargo CA Jr. Multicenter study of clinical features of sudden-onset versus slower-onset asthma exacerbations requiring hospitalization. Respir Care 2007; 52:1013.</a></li><li><a class="nounderline abstract_t">de Magalhães Simões S, dos Santos MA, da Silva Oliveira M, et al. Inflammatory cell mapping of the respiratory tract in fatal asthma. Clin Exp Allergy 2005; 35:602.</a></li><li><a class="nounderline abstract_t">DUNNILL MS. The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol 1960; 13:27.</a></li><li><a class="nounderline abstract_t">James AL, Elliot JG, Abramson MJ, Walters EH. Time to death, airway wall inflammation and remodelling in fatal asthma. Eur Respir J 2005; 26:429.</a></li><li><a class="nounderline abstract_t">McFadden ER Jr, Warren EL. Observations on asthma mortality. Ann Intern Med 1997; 127:142.</a></li><li><a class="nounderline abstract_t">Turner MO, Noertjojo K, Vedal S, et al. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998; 157:1804.</a></li><li><a class="nounderline abstract_t">Kolbe J, Fergusson W, Garrett J. Rapid onset asthma: a severe but uncommon manifestation. Thorax 1998; 53:241.</a></li><li><a class="nounderline abstract_t">Rodrigo GJ, Rodrigo C. Rapid-onset asthma attack: a prospective cohort study about characteristics and response to emergency department treatment. Chest 2000; 118:1547.</a></li><li><a class="nounderline abstract_t">Plaza V, Serrano J, Picado C, et al. Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma. Eur Respir J 2002; 19:846.</a></li><li><a class="nounderline abstract_t">Reid LM. The presence or absence of bronchial mucus in fatal asthma. J Allergy Clin Immunol 1987; 80:415.</a></li><li><a class="nounderline abstract_t">Sur S, Crotty TB, Kephart GM, et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis 1993; 148:713.</a></li><li><a class="nounderline abstract_t">Perskvist N, Edston E. Differential accumulation of pulmonary and cardiac mast cell-subsets and eosinophils between fatal anaphylaxis and asthma death: a postmortem comparative study. Forensic Sci Int 2007; 169:43.</a></li><li><a class="nounderline abstract_t">Eisner MD, Lieu TA, Chi F, et al. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J 2001; 17:233.</a></li><li><a class="nounderline abstract_t">Malmström K, Kaila M, Kajosaari M, et al. Fatal asthma in Finnish children and adolescents 1976-1998: validity of death certificates and a clinical description. Pediatr Pulmonol 2007; 42:210.</a></li><li><a class="nounderline abstract_t">Ekström M, Nwaru BI, Wiklund F, et al. Risk of Rehospitalization and Death in Patients Hospitalized Due to Asthma. J Allergy Clin Immunol Pract 2021; 9:1960.</a></li><li class="breakAll">2023 Global Initiative for Asthma (GINA) Report: Global Strategy for Asthma Management and Prevention. www.ginasthma.org/2023-gina-main-report (Accessed on May 15, 2023).</li><li><a class="nounderline abstract_t">Dhuper S, Maggiore D, Chung V, Shim C. Profile of near-fatal asthma in an inner-city hospital. Chest 2003; 124:1880.</a></li><li><a class="nounderline abstract_t">Mitchell I, Tough SC, Semple LK, et al. Near-fatal asthma: a population-based study of risk factors. Chest 2002; 121:1407.</a></li><li><a class="nounderline abstract_t">Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis 1992; 146:76.</a></li><li><a class="nounderline abstract_t">Goeman DP, Abramson MJ, McCarthy EA, et al. Asthma mortality in Australia in the 21st century: a case series analysis. BMJ Open 2013; 3.</a></li><li><a class="nounderline abstract_t">Bush RK, Prochnau JJ. Alternaria-induced asthma. J Allergy Clin Immunol 2004; 113:227.</a></li><li><a class="nounderline abstract_t">Osborne ML, Pedula KL, O'Hollaren M, et al. Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study. Chest 2007; 132:1151.</a></li><li><a class="nounderline abstract_t">Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.</a></li><li><a class="nounderline abstract_t">Roberts G, Patel N, Levi-Schaffer F, et al. Food allergy as a risk factor for life-threatening asthma in childhood: a case-controlled study. J Allergy Clin Immunol 2003; 112:168.</a></li><li><a class="nounderline abstract_t">Yoshimine F, Hasegawa T, Suzuki E, et al. Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan. Respirology 2005; 10:477.</a></li><li><a class="nounderline abstract_t">Becker JM, Rogers J, Rossini G, et al. Asthma deaths during sports: report of a 7-year experience. J Allergy Clin Immunol 2004; 113:264.</a></li><li><a class="nounderline abstract_t">Levine M, Iliescu ME, Margellos-Anast H, et al. The effects of cocaine and heroin use on intubation rates and hospital utilization in patients with acute asthma exacerbations. Chest 2005; 128:1951.</a></li><li><a class="nounderline abstract_t">Krantz AJ, Hershow RC, Prachand N, et al. Heroin insufflation as a trigger for patients with life-threatening asthma. Chest 2003; 123:510.</a></li><li><a class="nounderline abstract_t">Martinez-Moragón E, Plaza V, Serrano J, et al. Near-fatal asthma related to menstruation. J Allergy Clin Immunol 2004; 113:242.</a></li><li><a class="nounderline abstract_t">Tan WC, Xiang X, Qiu D, et al. Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease. Am J Med 2003; 115:272.</a></li><li><a class="nounderline abstract_t">Grandbastien M, Piotin A, Godet J, et al. SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation. J Allergy Clin Immunol Pract 2020; 8:2600.</a></li><li><a class="nounderline abstract_t">Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J 2013; 41:716.</a></li><li><a class="nounderline abstract_t">Engelkes M, de Ridder MA, Svensson E, et al. Multinational cohort study of mortality in patients with asthma and severe asthma. Respir Med 2020; 165:105919.</a></li><li><a class="nounderline abstract_t">Clapp PW, Peden DB, Jaspers I. E-cigarettes, vaping-related pulmonary illnesses, and asthma: A perspective from inhalation toxicologists. J Allergy Clin Immunol 2020; 145:97.</a></li><li><a class="nounderline abstract_t">Werner AK, Koumans EH, Chatham-Stephens K, et al. Hospitalizations and Deaths Associated with EVALI. N Engl J Med 2020; 382:1589.</a></li><li><a class="nounderline abstract_t">Cho JH, Paik SY. Association between Electronic Cigarette Use and Asthma among High School Students in South Korea. PLoS One 2016; 11:e0151022.</a></li><li><a class="nounderline abstract_t">Bayly JE, Bernat D, Porter L, Choi K. Secondhand Exposure to Aerosols From Electronic Nicotine Delivery Systems and Asthma Exacerbations Among Youth With Asthma. Chest 2019; 155:88.</a></li><li><a class="nounderline abstract_t">Strunk RC. Identification of the fatality-prone subject with asthma. J Allergy Clin Immunol 1989; 83:477.</a></li><li><a class="nounderline abstract_t">Strunk RC. Death due to asthma. New insights into sudden unexpected deaths, but the focus remains on prevention. Am Rev Respir Dis 1993; 148:550.</a></li><li><a class="nounderline abstract_t">Barr RG, Woodruff PG, Clark S, Camargo CA Jr. Sudden-onset asthma exacerbations: clinical features, response to therapy, and 2-week follow-up. Multicenter Airway Research Collaboration (MARC) investigators. Eur Respir J 2000; 15:266.</a></li><li><a class="nounderline abstract_t">Watson L, Turk F, James P, Holgate ST. Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. Respir Med 2007; 101:1659.</a></li><li><a class="nounderline abstract_t">Tsai CL, Lee WY, Hanania NA, Camargo CA Jr. Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008. J Allergy Clin Immunol 2012; 129:1252.</a></li><li><a class="nounderline abstract_t">Gelb AF, Schein A, Nussbaum E, et al. Risk factors for near-fatal asthma. Chest 2004; 126:1138.</a></li><li><a class="nounderline abstract_t">Kitch BT, Paltiel AD, Kuntz KM, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004; 126:1875.</a></li><li><a class="nounderline abstract_t">Boushey H, Enright P. Spirometry enhances identification of high-risk patients with asthma. Chest 2007; 132:1112.</a></li><li><a class="nounderline abstract_t">Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol 2001; 107:61.</a></li><li><a class="nounderline abstract_t">Miller MK, Lee JH, Blanc PD, et al. TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma. Eur Respir J 2006; 28:1145.</a></li><li><a class="nounderline abstract_t">Sorkness RL, Bleecker ER, Busse WW, et al. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol (1985) 2008; 104:394.</a></li><li><a class="nounderline abstract_t">Kikuchi Y, Okabe S, Tamura G, et al. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 1994; 330:1329.</a></li><li><a class="nounderline abstract_t">Bijl-Hofland ID, Cloosterman SG, Folgering HT, et al. Relation of the perception of airway obstruction to the severity of asthma. Thorax 1999; 54:15.</a></li><li><a class="nounderline abstract_t">Serrano J, Plaza V, Sureda B, et al. Alexithymia: a relevant psychological variable in near-fatal asthma. Eur Respir J 2006; 28:296.</a></li><li><a class="nounderline abstract_t">Ruffin RE, Latimer KM, Schembri DA. Longitudinal study of near fatal asthma. Chest 1991; 99:77.</a></li><li><a class="nounderline abstract_t">Motomura C, Odajima H, Tezuka J, et al. Perception of dyspnea during acetylcholine-induced bronchoconstriction in asthmatic children. Ann Allergy Asthma Immunol 2009; 102:121.</a></li><li><a class="nounderline abstract_t">Magadle R, Berar-Yanay N, Weiner P. The risk of hospitalization and near-fatal and fatal asthma in relation to the perception of dyspnea. Chest 2002; 121:329.</a></li><li><a class="nounderline abstract_t">Barreiro E, Gea J, Sanjuás C, et al. Dyspnoea at rest and at the end of different exercises in patients with near-fatal asthma. Eur Respir J 2004; 24:219.</a></li><li><a class="nounderline abstract_t">Nannini LJ, Zaietta GA, Guerrera AJ, et al. Breath-holding test in subjects with near-fatal asthma. A new index for dyspnea perception. Respir Med 2007; 101:246.</a></li><li><a class="nounderline abstract_t">George MR, O'Dowd LC, Martin I, et al. A comprehensive educational program improves clinical outcome measures in inner-city patients with asthma. Arch Intern Med 1999; 159:1710.</a></li><li><a class="nounderline abstract_t">Cowie RL, Revitt SG, Underwood MF, Field SK. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. Chest 1997; 112:1534.</a></li></ol></div><div id="topicVersionRevision">Topic 565 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Royal College of Physicians. Why asthma still kills: National Review of Asthma Deaths (NRAD). http://www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf (Accessed on May 16, 2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="www.worldlifeexpectancy.com/cause-of-death/asthma/by-country" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : www.worldlifeexpectancy.com/cause-of-death/asthma/by-country (Accessed on September 22, 2017).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973621" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Trends and Patterns of Differences in Chronic Respiratory Disease Mortality Among US Counties, 1980-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28797514" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32963117" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Asthma and all-cause mortality in children and young adults: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29461632" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Higher mortality of adults with asthma: A 15-year follow-up of a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17947969" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : National surveillance for asthma--United States, 1980-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24252609" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : National surveillance of asthma: United States, 2001-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24252609" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : National surveillance of asthma: United States, 2001-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31399437" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Asthma deaths rise 33% in past decade in England and Wales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27041475" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Severe or life-threatening asthma exacerbation: patient heterogeneity identified by cluster analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17430352" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Near-fatal asthma phenotype in the ENFUMOSA Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18043271" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Near-fatal asthma: recognition and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28295424" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Long-term future risk of severe exacerbations: Distinct 5-year trajectories of problematic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11686864" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk factors for hospitalization among adults with asthma: the influence of sociodemographic factors and asthma severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16778163" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mortality in patients hospitalized for asthma exacerbations in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23471206" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Long-term mortality among adults with asthma: a 25-year follow-up of 1,075 outpatients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15849323" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Severe asthma in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17650357" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Multicenter study of clinical features of sudden-onset versus slower-onset asthma exacerbations requiring hospitalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15898982" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Inflammatory cell mapping of the respiratory tract in fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13818688" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The pathology of asthma, with special reference to changes in the bronchial mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135723" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Time to death, airway wall inflammation and remodelling in fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9230005" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Observations on asthma mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9620909" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9741364" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Rapid onset asthma: a severe but uncommon manifestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11115438" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rapid-onset asthma attack: a prospective cohort study about characteristics and response to emergency department treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12030723" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3624695" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The presence or absence of bronchial mucus in fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8368644" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17081716" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Differential accumulation of pulmonary and cardiac mast cell-subsets and eosinophils between fatal anaphylaxis and asthma death: a postmortem comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11334125" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17245733" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fatal asthma in Finnish children and adolescents 1976-1998: validity of death certificates and a clinical description.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33359587" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk of Rehospitalization and Death in Patients Hospitalized Due to Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33359587" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk of Rehospitalization and Death in Patients Hospitalized Due to Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14605063" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Profile of near-fatal asthma in an inner-city hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12006421" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Near-fatal asthma: a population-based study of risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1626819" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23793664" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Asthma mortality in Australia in the 21st century: a case series analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767434" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Alternaria-induced asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573515" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349682" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Further fatal allergic reactions to food in the United Kingdom, 1999-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847494" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Food allergy as a risk factor for life-threatening asthma in childhood: a case-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135171" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Contribution of aspirin-intolerant asthma to near fatal asthma based on a questionnaire survey in Niigata Prefecture, Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767440" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Asthma deaths during sports: report of a 7-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236840" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The effects of cocaine and heroin use on intubation rates and hospital utilization in patients with acute asthma exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576374" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Heroin insufflation as a trigger for patients with life-threatening asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14767436" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Near-fatal asthma related to menstruation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12967691" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Epidemiology of respiratory viruses in patients hospitalized with near-fatal asthma, acute exacerbations of asthma, or chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32603901" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22903959" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Smoking and asthma: dangerous liaisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32174450" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Multinational cohort study of mortality in patients with asthma and severe asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31715190" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : E-cigarettes, vaping-related pulmonary illnesses, and asthma: A perspective from inhalation toxicologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32320569" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hospitalizations and Deaths Associated with EVALI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26942764" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Association between Electronic Cigarette Use and Asthma among High School Students in South Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30359612" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Secondhand Exposure to Aerosols From Electronic Nicotine Delivery Systems and Asthma Exacerbations Among Youth With Asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2645346" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Identification of the fatality-prone subject with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8368621" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Death due to asthma. New insights into sudden unexpected deaths, but the focus remains on prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706490" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sudden-onset asthma exacerbations: clinical features, response to therapy, and 2-week follow-up. Multicenter Airway Research Collaboration (MARC) investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17462875" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Factors associated with mortality after an asthma admission: a national United Kingdom database analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22385630" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Age-related differences in clinical outcomes for acute asthma in the United States, 2006-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486375" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Risk factors for near-fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596687" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17934110" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Spirometry enhances identification of high-risk patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11149992" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : FEV(1) is associated with risk of asthma attacks in a pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16870656" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17991792" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8152444" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10343625" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Relation of the perception of airway obstruction to the severity of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16571616" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Alexithymia: a relevant psychological variable in near-fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984991" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Longitudinal study of near fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19230462" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Perception of dyspnea during acetylcholine-induced bronchoconstriction in asthmatic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834639" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The risk of hospitalization and near-fatal and fatal asthma in relation to the perception of dyspnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15332388" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Dyspnoea at rest and at the end of different exercises in patients with near-fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16824744" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Breath-holding test in subjects with near-fatal asthma. A new index for dyspnea perception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10448773" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A comprehensive educational program improves clinical outcome measures in inner-city patients with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9404750" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The effect of a peak flow-based action plan in the prevention of exacerbations of asthma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
